Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Top Cited Papers
Open Access
- 1 December 2020
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 396 (10267) , 1979-1993
- https://doi.org/10.1016/s0140-6736(20)32466-1
Abstract
No abstract availableKeywords
Funding Information
- National Institute for Health Research
- Coalition for Epidemic Preparedness Innovations
- UK Research and Innovation
This publication has 27 references indexed in Scilit:
- A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime – MVA85A boost in healthy UK adultsPublished by Elsevier ,2019
- Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adultsJournal of Infection, 2019
- Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy AdultsEBioMedicine, 2018
- A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVANew England Journal of Medicine, 2016
- Safety and Immunogenicity of Novel Adenovirus Type 26– and Modified Vaccinia Ankara–Vectored Ebola VaccinesJAMA, 2016
- A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative ImmunogenicityPLOS ONE, 2012
- Immunosenescence: emerging challenges for an ageing populationImmunology, 2007
- Antibody response to influenza vaccination in the elderly: A quantitative reviewVaccine, 2006
- A global clinical measure of fitness and frailty in elderly peopleCMAJ : Canadian Medical Association Journal, 2005
- Hepatitis-B Vaccination in the ElderlyThe Journal of Infectious Diseases, 1984